Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 637,865
  • Shares Outstanding, K 49,256
  • Annual Sales, $ 90,240 K
  • Annual Income, $ -263,490 K
  • 60-Month Beta 1.22
  • Price/Sales 6.98
  • Price/Cash Flow N/A
  • Price/Book 1.82
Trade RGNX with:

Options Overview Details

View History
  • Implied Volatility 77.23% ( +0.37%)
  • Historical Volatility 54.97%
  • IV Percentile 41%
  • IV Rank 23.04%
  • IV High 165.65% on 08/05/24
  • IV Low 50.77% on 11/17/23
  • Put/Call Vol Ratio 8.00
  • Today's Volume 18
  • Volume Avg (30-Day) 28
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 2,924
  • Open Int (30-Day) 2,779

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -1.16
  • Number of Estimates 3
  • High Estimate -1.09
  • Low Estimate -1.28
  • Prior Year -1.41
  • Growth Rate Est. (year over year) +17.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.08 +13.09%
on 09/05/24
13.48 -7.05%
on 09/17/24
+0.28 (+2.29%)
since 08/16/24
3-Month
10.49 +19.45%
on 07/08/24
15.36 -18.42%
on 07/29/24
+0.32 (+2.62%)
since 06/18/24
52-Week
10.49 +19.45%
on 07/08/24
28.80 -56.49%
on 03/05/24
-5.28 (-29.65%)
since 09/18/23

Most Recent Stories

More News
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END

SBFM : 2.99 (+5.65%)
NVAX : 12.56 (-2.86%)
RGNX : 12.53 (-3.24%)
BNTX : 115.62 (-7.29%)
ABBV : 192.94 (-0.26%)
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth

SBFM : 2.99 (+5.65%)
NVAX : 12.56 (-2.86%)
RGNX : 12.53 (-3.24%)
BNTX : 115.62 (-7.29%)
ABBV : 192.94 (-0.26%)
Regenxbio: Q2 Earnings Snapshot

Regenxbio: Q2 Earnings Snapshot

RGNX : 12.53 (-3.24%)
Regenxbio: Q1 Earnings Snapshot

Regenxbio: Q1 Earnings Snapshot

RGNX : 12.53 (-3.24%)
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

The threat is still emerging, but it could be significant.

SRPT : 125.01 (-0.54%)
RGNX : 12.53 (-3.24%)
Regenxbio: Q4 Earnings Snapshot

Regenxbio: Q4 Earnings Snapshot

RGNX : 12.53 (-3.24%)
Regenxbio: Q3 Earnings Snapshot

Regenxbio: Q3 Earnings Snapshot

RGNX : 12.53 (-3.24%)
REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023. Jefferies...

RGNX : 12.53 (-3.24%)
REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNEâ„¢ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be...

RGNX : 12.53 (-3.24%)
REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in...

RGNX : 12.53 (-3.24%)

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 13.65
2nd Resistance Point 13.33
1st Resistance Point 12.93
Last Price 12.53
1st Support Level 12.21
2nd Support Level 11.89
3rd Support Level 11.49

See More

52-Week High 28.80
Fibonacci 61.8% 21.81
Fibonacci 50% 19.65
Fibonacci 38.2% 17.48
Last Price 12.53
52-Week Low 10.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar